1938 - CoviLiv™, a Novel Intranasal Live-Attenuated COVID-19 Vaccine Candidate, Induces Robust Humoral and Cellular Immunity in First-In-Human Clinical Trial CDX-CoV-001

Presenting Author(s)

• 

  Johanna K. Kaufmann, PhD (she/her/hers)

  EVP Oncology and Immunology
  Codagenix Inc.
  Cambridge, MA, United States

  Slides

Co-Author(s)

• KW

  Keri Wyllie, MPA

  Associate Director, Translational Biology
  Codagenix Inc.
  Farmingdale, New York, United States
• YZ

  Yiwen Zhao, PhD

  Scientist, Immuno-Oncology
  Codagenix Inc.
  Cambridge, Massachusetts, United States
• LT

  Lasmy Tea, MS, MPH

  Associate Director, Clinical Project Management
  Codagenix Inc.
  Farmingdale, New York, United States
• 

  Sybil Tasker, MD, MPH, FIDSA

  Chief Medical Officer
  Codagenix Inc.
  Farmingdale, New York, United States
• LY

  Leena R. Yeolekar, PhD

  Scientist
  Serum Institute of India Pvt. Ltd.
  Pune, Maharashtra, India
• RD

  Rajeev Dhere, PhD

  Executive Director
  Serum Institute of India Pvt. Ltd.
  Pune, Maharashtra, India
• SM

  Steffen Mueller, PhD

  CSO
  Codagenix, Inc
  Farmingdale, NY, United States